Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

The Natural History of Untreated Muscle Invasive Bladder Cancer.

Martini A, Sfakianos JP, Renström-Koskela L, Mortezavi A, Falagario UG, Egevad L, Hosseini A, Mehrazin R, Galsky MD, Steineck G, Wiklund NP.

BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872. [Epub ahead of print]

PMID:
31310696
2.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD.

Eur Urol. 2019 Jul 1. pii: S0302-2838(19)30515-9. doi: 10.1016/j.eururo.2019.06.025. [Epub ahead of print]

PMID:
31272788
3.

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD.

Eur Urol. 2019 Jun 11. pii: S0302-2838(19)30444-0. doi: 10.1016/j.eururo.2019.05.037. [Epub ahead of print] Review.

PMID:
31200951
4.

Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach.

Mohamed N, Leung TM, Shah QN, Pisipati S, Berry DL, Benn EKT, Lee CT, Hall S, Mehrazin R, Sfakianos J.

J Cancer Educ. 2019 Jun 7. doi: 10.1007/s13187-019-01534-1. [Epub ahead of print]

PMID:
31175566
5.

Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.

Kaldany A, Paulucci DJ, Kannappan M, Beksac AT, Anastos H, Okhawere K, Sfakianos JP, Badani KK.

Urol Oncol. 2019 Jun 5. pii: S1078-1439(19)30194-2. doi: 10.1016/j.urolonc.2019.05.008. [Epub ahead of print]

PMID:
31174958
6.

Trends and outcomes in contemporary management renal cell carcinoma and vena cava thrombus.

Beksac AT, Shah QN, Paulucci DJ, Lo JZ, Okhawere KE, Elbakry AA, Dayal BD, Mehrazin R, Eun D, Hemal A, Abaza R, Sfakianos JP, Badani KK.

Urol Oncol. 2019 Jun 5. pii: S1078-1439(19)30196-6. doi: 10.1016/j.urolonc.2019.05.010. [Epub ahead of print]

PMID:
31174956
7.

Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1 - cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy.

Daza J, Beksac AT, Kannappan M, Chong J, Abaza R, Hemal A, Sfakianos JP, Badani KK.

Minerva Urol Nefrol. 2019 Jun 4. doi: 10.23736/S0393-2249.19.03440-4. [Epub ahead of print]

PMID:
31166101
8.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 May 31. doi: 10.1002/cncr.32169. [Epub ahead of print]

PMID:
31150110
9.

The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer.

Waingankar N, Jia R, Marqueen KE, Audenet F, Sfakianos JP, Mehrazin R, Ferket BS, Mazumdar M, Galsky MD.

Urol Oncol. 2019 May 18. pii: S1078-1439(19)30160-7. doi: 10.1016/j.urolonc.2019.04.027. [Epub ahead of print]

PMID:
31109837
10.

Management of high complexity renal masses in partial nephrectomy: A multicenter analysis.

Beksac AT, Okhawere KE, Elbakry AA, Dayal BD, Paulucci DJ, Rothberg MB, Sfakianos JP, Abaza R, Eun DD, Bhandari A, Hemal AK, Porter J, Badani KK.

Urol Oncol. 2019 Jul;37(7):437-444. doi: 10.1016/j.urolonc.2019.04.019. Epub 2019 May 16.

PMID:
31103334
11.

Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management.

Martini A, Sfakianos JP, Paulucci DJ, Abaza R, Eun DD, Bhandari A, Hemal AK, Badani KK.

Urol Oncol. 2019 Jul;37(7):445-451. doi: 10.1016/j.urolonc.2019.04.018. Epub 2019 May 8.

PMID:
31076354
12.

A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.

Martini A, Wang J, Brown NM, Cumarasamy S, Sfakianos JP, Rastinehad AR, Haines KG 3rd, Wiklund NP, Nair SS, Tewari AK.

BJU Int. 2019 Jul;124(1):155-162. doi: 10.1111/bju.14740. Epub 2019 Apr 3.

PMID:
30825357
13.

Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Martini A, Daza J, Poltiyelova E, Gul Z, Heard JR, Ferket BS, Waingankar N, Galsky MD, Sfakianos JP.

BJU Int. 2019 Feb 23. doi: 10.1111/bju.14719. [Epub ahead of print]

PMID:
30801918
14.

Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion.

Audenet F, Attalla K, Giordano M, Pfail J, Lubin MA, Waingankar N, Gainsburg D, Badani KK, Sim A, Sfakianos JP.

Urol Oncol. 2019 May;37(5):300.e17-300.e23. doi: 10.1016/j.urolonc.2019.02.002. Epub 2019 Feb 16.

PMID:
30777392
15.

Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.

Marqueen KE, Waingankar N, Sfakianos JP, Mehrazin R, Niglio SA, Audenet F, Jia R, Mazumdar M, Ferket BS, Galsky MD.

JNCI Cancer Spectr. 2018 Nov;2(4):pky075. doi: 10.1093/jncics/pky075. Epub 2019 Jan 28.

16.

Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma.

Beksac AT, Bicak M, Paranjpe I, Paulucci DJ, Sfakianos JP, Badani KK.

Clin Genitourin Cancer. 2019 Apr;17(2):e314-e322. doi: 10.1016/j.clgc.2018.12.002. Epub 2018 Dec 8.

PMID:
30639042
17.

Comparison of overall survival and unplanned hospital readmissions between partial and radical nephrectomy for cT1a and cT1b renal masses.

Chong JT, Paulucci D, Lubin M, Beksac AT, Gin G, Sfakianos JP, Badani KK.

Ther Adv Urol. 2018 Nov 9;10(12):383-391. doi: 10.1177/1756287218810313. eCollection 2018 Dec.

18.

A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE.

Urol Oncol. 2019 Feb;37(2):116-122. doi: 10.1016/j.urolonc.2018.11.011. Epub 2018 Dec 1.

PMID:
30509868
19.

Image guidance in robot-assisted radical prostatectomy: how far do we stand?

Martini A, Wagaskar VG, Dell'Oglio P, Rastinehad AR, Sfakianos JP, Tewari AK.

Curr Opin Urol. 2019 Jan;29(1):10-13. doi: 10.1097/MOU.0000000000000565.

PMID:
30489328
20.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
21.

Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device.

Ghanaat M, Winer AG, Sjoberg DD, Poon BY, Kashan M, Tin AL, Sfakianos JP, Cha EK, Donahue TF, Dalbagni G, Herr HW, Bochner BH, Vickers AJ, Donat SM.

Urology. 2018 Dec;122:121-126. doi: 10.1016/j.urology.2018.09.010. Epub 2018 Sep 20.

PMID:
30244117
22.

Risk factors and prognostic implications for pathologic upstaging to T3a after partial nephrectomy.

Beksac AT, Paulucci DJ, Gul Z, Reddy BN, Kannappan M, Martini A, Sfakianos JP, Gin GE, Abaza R, Eun DD, Bhandari A, Hemal AK, Porter J, Badani KK.

Minerva Urol Nefrol. 2018 Sep 19. doi: 10.23736/S0393-2249.18.03210-1. [Epub ahead of print]

PMID:
30230296
23.

Current Role of Checkpoint Inhibitors in Urologic Cancers.

Attalla K, Sfakianos JP, Galsky MD.

Cancer Treat Res. 2018;175:241-258. doi: 10.1007/978-3-319-93339-9_11.

PMID:
30168125
24.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.

Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.

25.

Dealing with perioperative antiplatelet treatment for transurethral resection of the bladder: primum non nocere.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2018 May;7(Suppl 2):S258-S259. doi: 10.21037/tau.2018.03.24. No abstract available.

26.

An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States.

Kaldany A, Blum KA, Paulucci DJ, Beksac AT, Jayaratna I, Sfakianos JP, Badani KK.

Urol Oncol. 2018 Aug;36(8):363.e1-363.e6. doi: 10.1016/j.urolonc.2018.05.006. Epub 2018 Jun 6.

PMID:
29884343
27.

Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.

Audenet F, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP, Galsky MD.

J Urol. 2018 Nov;200(5):996-1004. doi: 10.1016/j.juro.2018.06.001. Epub 2018 Jun 4.

PMID:
29879397
28.

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.

Audenet F, Farkas AM, Anastos H, Galsky MD, Bhardwaj N, Sfakianos JP.

World J Urol. 2018 Nov;36(11):1741-1748. doi: 10.1007/s00345-018-2359-7. Epub 2018 Jun 2.

PMID:
29860605
29.

Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.

Cha EK, Sfakianos JP, Sukhu R, Yee AM, Sjoberg DD, Bochner BH.

BJU Int. 2018 Oct;122(4):627-632. doi: 10.1111/bju.14242. Epub 2018 May 4.

PMID:
29633530
30.

The evolution of bladder cancer genomics: What have we learned and how can we use it?

Audenet F, Attalla K, Sfakianos JP.

Urol Oncol. 2018 Jul;36(7):313-320. doi: 10.1016/j.urolonc.2018.02.017. Epub 2018 Mar 21. Review.

PMID:
29573965
31.

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.

Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol Focus. 2019 May;5(3):365-368. doi: 10.1016/j.euf.2018.01.005. Epub 2018 Feb 1.

PMID:
29396293
32.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

33.

Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome.

Donahu TF, Bagrodia A, Audenet F, Donoghue MTA, Cha EK, Sfakianos JP, Sperling D, Al-Ahmadie H, Clendenning M, Rosty C, Buchanan DD, Jenkins M, Hopper J, Winship I, Templeton AS, Walsh MF, Stadler ZK, Iyer G, Taylor B, Coleman J, Lindor NM, Solit DB, Bochner BH.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00143.

34.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
35.

Psychosocial impact of penile carcinoma.

Audenet F, Sfakianos JP.

Transl Androl Urol. 2017 Oct;6(5):874-878. doi: 10.21037/tau.2017.07.24. Review.

36.

Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature.

Audenet F, Sfakianos JP.

Bladder Cancer. 2017 Oct 27;3(4):231-236. doi: 10.3233/BLC-170127. Review.

37.

Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer.

Galsky MD, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao CK, Sfakianos J, Mehrazin R, Waingankar N, Oh WK, Mazumdar M, Ferket BS.

JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00116.

38.

Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.

Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK.

JCO Clin Cancer Inform. 2017 Nov;1:1-10. doi: 10.1200/CCI.17.00044.

39.

Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database.

Attalla K, Paulucci DJ, Blum K, Anastos H, Moses KA, Badani KK, Spiess PE, Sfakianos JP.

Urol Oncol. 2018 Jan;36(1):14.e17-14.e24. doi: 10.1016/j.urolonc.2017.09.014. Epub 2017 Oct 12.

PMID:
29031418
40.

Management of Atypical Renal Cell Carcinomas.

Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK.

Curr Treat Options Oncol. 2017 Sep 14;18(10):61. doi: 10.1007/s11864-017-0501-1. Review.

PMID:
28913767
41.

Heterogeneity in renal cell carcinoma.

Beksac AT, Paulucci DJ, Blum KA, Yadav SS, Sfakianos JP, Badani KK.

Urol Oncol. 2017 Aug;35(8):507-515. doi: 10.1016/j.urolonc.2017.05.006. Epub 2017 May 24. Review.

PMID:
28551412
42.

Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.

Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK.

Ther Adv Med Oncol. 2017 Apr;9(4):287-298. doi: 10.1177/1758834016687261. Epub 2017 Feb 14. Review.

43.

Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?

Galsky MD, Sfakianos JP, Ferket BS.

Eur Urol. 2017 Oct;72(4):555-556. doi: 10.1016/j.eururo.2017.04.012. Epub 2017 Apr 19. No abstract available.

PMID:
28433377
44.

Predicting Complications Following Robot-Assisted Partial Nephrectomy with the ACS NSQIP® Universal Surgical Risk Calculator.

Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD, Bhandari A, Hemal AK, Sfakianos JP, Badani KK.

J Urol. 2017 Oct;198(4):803-809. doi: 10.1016/j.juro.2017.04.021. Epub 2017 Apr 9.

PMID:
28400189
45.

Trends in management of the small renal mass in renal transplant recipient candidates: A multi-institutional survey analysis.

Beksac AT, Paulucci DJ, Sfakianos JP, Reddy BN, Gin GE, Lerner SM, Badani KK.

Urol Oncol. 2017 Aug;35(8):529.e17-529.e22. doi: 10.1016/j.urolonc.2017.03.012. Epub 2017 Apr 5.

PMID:
28391999
46.

Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma.

Gin GE, Ruel NH, Kardos SV, Sfakianos JP, Uchio E, Lau CS, Yuh BE.

Urol Oncol. 2017 May;35(5):192-200. doi: 10.1016/j.urolonc.2016.11.017. Epub 2016 Dec 29.

PMID:
28041996
47.

Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma.

Paulucci DJ, Sfakianos JP, Skanderup AJ, Kan K, Tsao CK, Galsky MD, Hakimi AA, Badani KK.

Oncotarget. 2017 Jan 17;8(3):5196-5205. doi: 10.18632/oncotarget.14122.

48.

Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.

Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.

Urol Oncol. 2017 Apr;35(4):151.e9-151.e15. doi: 10.1016/j.urolonc.2016.11.002. Epub 2016 Dec 5.

49.

The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.

Sagalovich D, Leapman M, Sfakianos J, Hall S, Stock R, Stone N.

Brachytherapy. 2016 Nov - Dec;15(6):730-735. doi: 10.1016/j.brachy.2016.09.005. Epub 2016 Oct 12.

PMID:
27743956
50.

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.

Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD.

Oncologist. 2016 Dec;21(12):1414-e9. Epub 2016 Oct 14.

Supplemental Content

Loading ...
Support Center